Literature DB >> 15948929

Modelling approaches to dose estimation in children.

Trevor N Johnson1.   

Abstract

Most of the drugs on the market are originally developed for adults and dosage selection is based on an optimal balance between clinical efficacy and safety. The aphorism 'children are not small adults' not only holds true for the selection of suitable drugs and dosages for use in children but also their susceptibility to adverse drug reactions. Since children may not be subject to dose escalation studies similar to those carried out in the adult population, some initial estimation of dose in paediatrics should be obtained via extrapolation approaches. However, following such an exercise, well-conducted PK-PD or PK studies will still be needed to determine the most appropriate doses for neonates, infants, children and adolescents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948929      PMCID: PMC1884869          DOI: 10.1111/j.1365-2125.2005.02429.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

Review 1.  Clinical trial simulation in drug development.

Authors:  P L Bonate
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

2.  Design and power of a population pharmacokinetic study.

Authors:  P I Lee
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

Review 3.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices.

Authors:  J B Houston; D J Carlile
Journal:  Drug Metab Rev       Date:  1997-11       Impact factor: 4.518

Review 4.  Human body composition: in vivo methods.

Authors:  K J Ellis
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

5.  Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.

Authors:  H Takahashi; S Ishikawa; S Nomoto; Y Nishigaki; F Ando; T Kashima; S Kimura; M Kanamori; H Echizen
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

6.  Developmental pharmacodynamics of cyclosporine.

Authors:  J D Marshall; G L Kearns
Journal:  Clin Pharmacol Ther       Date:  1999-07       Impact factor: 6.875

7.  Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.

Authors:  Agnès Tran; Elisabeth Rey; Gérard Pons; Ann Pariente-Khayat; Philippe D'Athis; Valentine Sallerin; Christophe Dupont
Journal:  Clin Pharmacol Ther       Date:  2002-05       Impact factor: 6.875

8.  Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux.

Authors:  S R Orenstein; J L Blumer; H M Faessel; J A McGuire; K Fung; B U K Li; J E Lavine; J E Grunow; W R Treem; A A Ciociola
Journal:  Aliment Pharmacol Ther       Date:  2002-05       Impact factor: 8.171

9.  The pharmacodynamics and pharmacokinetics of mivacurium in children.

Authors:  D ØStergaard; M R Gätke; H Berg; S N Rasmussen; J Viby-Mogensen
Journal:  Acta Anaesthesiol Scand       Date:  2002-05       Impact factor: 2.105

10.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

Authors:  R S Obach; J G Baxter; T E Liston; B M Silber; B C Jones; F MacIntyre; D J Rance; P Wastall
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

View more
  25 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

2.  Testing new drugs in naked apes and getting the dose right in their young.

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

3.  What is the right dose for children?

Authors:  Massimo Cella; Catherijne Knibbe; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

4.  Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.

Authors:  Massimo Cella; Catherijne Knibbe; Saskia N de Wildt; Joop Van Gerven; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 5.  To scale or not to scale: the principles of dose extrapolation.

Authors:  Vijay Sharma; John H McNeill
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

6.  Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.

Authors:  Efthymios Manolis; Gérard Pons
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

Review 7.  The role of population PK-PD modelling in paediatric clinical research.

Authors:  Roosmarijn F W De Cock; Chiara Piana; Elke H J Krekels; Meindert Danhof; Karel Allegaert; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2010-03-26       Impact factor: 2.953

8.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 9.  Clinical trials in children.

Authors:  Pathma D Joseph; Jonathan C Craig; Patrina H Y Caldwell
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 10.  How to optimize the evaluation and use of antibiotics in neonates.

Authors:  Evelyne Jacqz-Aigrain; Florentia Kaguelidou; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-09-01       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.